Rakovina Therapeutics Inc (RKV) — Working Capital to Net Assets Ratio
Rakovina Therapeutics Inc (RKV) has a Working Capital to Net Assets ratio of -25.9% as of September 2025. Working capital of CA$-489.28K (current assets of CA$1.69 Million minus current liabilities of CA$2.18 Million) is measured against net assets of CA$1.89 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See RKV net asset quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Rakovina Therapeutics Inc Working Capital to Net Assets (2021–2024)
This chart shows how Rakovina Therapeutics Inc's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of September 2025, the ratio stands at -25.9%, reflecting working capital of CA$-489.28K against net assets of CA$1.89 Million CAD. Check Rakovina Therapeutics Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Rakovina Therapeutics Inc (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Rakovina Therapeutics Inc from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Rakovina Therapeutics Inc (RKV) total market value.
| Year | WC/NA Ratio | Working Capital (CAD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 7.5% | CA$321.44K | CA$4.30 Million | CA$2.26 Million | CA$1.94 Million | ▼ -5.6 pp |
| 2023 | 13.1% | CA$477.88K | CA$3.66 Million | CA$632.53K | CA$154.65K | ▼ -2.9 pp |
| 2022 | 16.0% | CA$962.55K | CA$6.01 Million | CA$1.07 Million | CA$107.05K | ▼ -18.6 pp |
| 2021 | 34.6% | CA$2.96 Million | CA$8.54 Million | CA$3.07 Million | CA$113.98K | — |